Anti-HLA-DQ antibodies are highly and independently related to the C1q-binding capacity of HLA antibodies

被引:4
|
作者
Arreola-Guerra, Jose M. [1 ]
Morales-Buenrostro, Luis E. [2 ]
Granados, Julio [1 ]
Castelan, Natalia [3 ]
de Santiago, Adrian [3 ]
Arvizu, Adriana [3 ]
Gonzalez-Tableros, Norma [3 ]
Lopez, Mayra [3 ]
Vilatoba, Mario [1 ]
Albertu, Josefina [1 ]
机构
[1] Natl Inst Med Sci & Nutr Salvador Zubiran, Dept Transplantat, Vasco Quiroga 15,Secc 16, Mexico City 14080, DF, Mexico
[2] Natl Inst Med Sci & Nutr Salvador Zubiran, Dept Nephrol Mineral Metab, Vasco Quiroga 15,Secc XVI, Mexico City 14080, DF, Mexico
[3] Natl Inst Med Sci & Nutr Salvador Zubiran, Histocompatibil Lab, Vasco Quiroga 15,Secc 16, Mexico City 14080, DF, Mexico
关键词
DONOR-SPECIFIC ANTIBODIES; C1Q ASSAY; COMPLEMENT-BINDING; MEDIATED REJECTION; CLINICAL-RELEVANCE; RISK; TRANSPLANTATION; STRENGTH; TITER;
D O I
10.1016/j.trim.2017.02.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The complement-binding capacity of anti-HLA antibodies (HLAabs) is recognized as a key pathogenic factor. The aim of this study is to describe the patient characteristics associated to the presence of C1q+ as well as those of the Abs per se when associated to C1q binding. Methodology: This is a cross-sectional, observational, descriptive study of patients with previous sensitizing factors and awaiting a kidney transplant (KT). We determined anti-HLA antibodies and their C1q binding capacity with the C1q assay. Results: Among the 55 included patients, 26 (47.2%) had at least one C1q + anti-HLAab. A previous transplant history, a greater number of HLAabs, a greater % of class I or class II PRA, the average MR of all HLAabs, the MR of the dominant HLAab and the HLAab antigenic specificities against HLA-B,-C and-DQ all proved to be risk factors associated to the presence of Cl q binding HLAabs (Clq +). In the total population, were detected 1268 HLAabs, 230 (18.1%) of which were Cl q +. On multivariate analysis, both HLAabs against the HLA-DQantigenic specificity (OR 9.82 95% CI 5.4-17.6, p < 0.001) and the MR documented by LABScreen (R) SAB (OR 12% Cl 1.22-1.3, p < 0.001), proved to be risk factors. Conclusion: Anti-HLA-DQ antibodies and the MFI (LABScreen (R) SAB) are highly and independently related to the C1q-binding capacity of HLA antibodies. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:10 / 16
页数:7
相关论文
共 50 条
  • [1] THE INCREASED COMPLEXITY OF THE ANALYSIS OF ANTI-HLA-DQ ANTIBODIES
    Ramalhete, Luis
    Rosario Sancho, M.
    Isabel Silva, M.
    Compadrinho, Artur
    Trindade, Helder
    TISSUE ANTIGENS, 2015, 85 (05): : 430 - 431
  • [2] Role of C1q-binding anti-HLA antibodies as a predictor of Lung allograft outcome
    Brugiere, Olivier
    Roux, Antoine
    Le Pavec, Jerome
    Sroussi, Deborah
    Parquin, Francois
    Pradere, Pauline
    Dupin, Clairelyne
    Bunel, Vincent
    Mourin, Gisele
    Jebrak, Gilles
    Dauriat, Gaelle
    Castier, Yves
    Mordant, Pierre
    Lortat-Jacob, Brice
    Jean-Baptiste, Sylvain
    Mal, Herve
    Suberbielle, Caroline
    Gautreau, Chantal
    Caillat-Zucman, Sophie
    Cazes, Aurelie
    Thabut, Gabriel
    Taupin, Jean-Luc
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (02)
  • [3] Effects of weak/non-complement-binding HLA antibodies on C1q-binding
    Honger, G.
    Amico, P.
    Arnold, M-L.
    Spriewald, B. M.
    Schaub, S.
    HLA, 2017, 90 (02) : 88 - 94
  • [4] From Mean Fluorescence Intensity to C1q-Binding: The Saga of Anti-HLA Donor-specific Antibodies
    Loupy, Alexandre
    Legendre, Christophe
    TRANSPLANTATION, 2015, 99 (06) : 1107 - 1108
  • [5] THE CLINICAL UTILITY OF PREFORMED C1Q-BINDING DONOR-SPECIFIC HLA ANTIBODIES IN KIDNEY TRANSPLANTATION
    Lee, Sua
    Ko, Eun Jeong
    Chung, Byung Ha
    Yang, Chul Woo
    TRANSPLANTATION, 2020, 104 (09) : S3 - S3
  • [6] C1q-Binding HLA Antibodies Do Not Predict Platelet Transfusion Failure in TRAP Study Participant
    Jackman, Rachael P.
    Bolgiano, Douglas
    Lebedeva, Mila
    Slichter, Sherrill J.
    Norris, Philip J.
    BLOOD, 2014, 124 (21)
  • [7] C1Q-BINDING ABILITY OF DONOR-SPECIFIC ANTI-HLA ANTIBODIES FACILITATES THE IDENTIFICATION OF HARMFUL ANTIBODIES ONLY PRE-TRANSPLANT
    Kauke, T.
    Oberhauser, C.
    Lin, V.
    Guba, M.
    Angele, M.
    Werner, J.
    Coenen, M.
    Fischereder, M.
    Meiser, B.
    Stangl, M.
    Habicht, A.
    TRANSPLANT INTERNATIONAL, 2015, 28 : 11 - 11
  • [8] C1Q-BINDING ABILITY OF DONOR-SPECIFIC ANTI-HLA ANTIBODIES FACILITATES THE IDENTIFICATION OF HARMFUL ANTIBODIES ONLY PRE-TRANSPLANT
    Kauke, Teresa
    Oberhauser, Cornelia
    Lin, Viviane
    Coenen, Michaela
    Angele, Martin
    Guba, Markus
    Werner, Jens
    Fischereder, Michael
    Meiser, Bruno
    Stangl, Manfred
    Habicht, Antje
    TRANSPLANT INTERNATIONAL, 2015, 28 : 126 - 126
  • [9] REACTIVITY OF HLA EPITOPE-SPECIFIC ANTIBODIES IN IG-BINDING, C1Q-BINDING AND LYMPHOCYTOTOXICITY ASSAYS
    Duquesnoy, Rene J.
    Marrari, Marilyn
    Mulder, Arend
    Claas, Frans
    HUMAN IMMUNOLOGY, 2012, 73 : 13 - 13
  • [10] C1Q-BINDING ANTI-HLA DONOR-SPECIFIC ANTIBODIES AND LONG-TERM KIDNEY GRAFT OUTCOMES
    Gniewkiewicz, Michal
    Czerwinska, Katarzyna
    Zielniok, Katarzyna
    Durlik, Magdalena
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I922 - I923